Skip to main content
Signal8

RADNOSTIX INC (INIS) Form 10-Q — Nov 16, 2026

$INISForm 10-QFiled Nov 16, 2026, 9:00 AM ET0001437749-26-037034Original filing

Radnostix reported a nine-month net loss of $3.07 million versus $477,080 a year earlier, as revenue fell 25% to $7.62 million following two voluntary recalls of its Generic Sodium Iodide I-131 and capsule products plus cobalt hot-cell shutdown and isotope supply outages. Cash dropped 58% to $711,288 at quarter-end, though liquidity support came via a $1.0 million Bank of Commerce revolver and a $500,000 related-party note, and the pending $13.5 million sale of its Fluorine Products segment to Nano Nuclear Energy should bring $9 million cash plus $4 million in NNE shares at closing.

Key figures

Eps
0
Revenue
7621744
Revenue Yoy
-25% (nine months ended Sep 30, 2026 vs 2025)
Total Assets
16854943
Cash Position
711288
Shares Outstanding
542145510
Q3 revenue
2571035
New revolver
1000000
Total equity
1927221
Duf6 sale value
13500000
Escrow released
500000
Restricted cash
1532733
Stock price otcqb
0.06
Series c preferred
4063000
Related party notes
2120000
Duf6 cash at closing
9000000
Duf6 restricted shares
4000000
Gross profit nine months
4024398

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.